The study aims to identify which Syde®-derived digital outcomes are reliable in FGFR3-related Skeletal Dysplasia. This requires to set-up a natural history study to measure limb movements in patients with ACH or HCH.
Eligibility
Sex
ALL
Min age
2 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria:
1.a. Aged 2 years old or older at the time of consent (France and Belgium)
1. b. Aged between 2 years old and \< 17 years old at the time of consent (United Kingdom)
2. Written informed consent obtained:
1. From the parent(s) or legal guardian(s) for participants under 18 years old.
2. From participants 18 years old and older.
3. Affiliated to, or beneficiary of a social security category (not applicable for the United Kingdom)
4. Able to walk unassisted for at least 10 meters.
5. Genetically confirmed diagnosis with one pathogenic variant (ACMG class IV \& V) of achondroplasia or hypochondroplasia.
6. Participant (and caregivers for participants under 18 years old) willing and able to comply with all study procedures including: questionnaires, Syde® related procedures
Exclusion Criteria:
1. Subjects who have short stature condition other than ACH/HCH.
2. Presence of cognitive disorders that limit their understanding of the data collection process (training of device use and 4-week recording periods every 6 months, device return at the end of the study), the implication of the study and consent.
3. Presence or history of any concurrent disease or condition that could interfere with study participation, impact pediatric growth, affect motor or balance or gait function (such as neurological, endocrine, infectious, allergic, osteoarthritis, or inflammatory), assessed by the investigator.
4. Females who are pregnant, or planning to become pregnant during the study duration.
5. Body Mass Index = 35 kg/m2.
6. Recent upper and/or lower limbs injury (trauma/fracture or surgery) in the 6 months preceding inclusion.
7. Prior limb lengthening surgery or planned or expected to have limb lengthening surgery while enrolled in the study.
8. Presence of guided growth hardware (such as 8-plates) or planned orthopedic surgeries during the study.
9. Vulnerable patient (guardianship, curatorship or safeguarding of justice), unable to provide informed consent or who is unable to express their consent.
Primary outcome measure(s)
Reliability of digital endpoint derived from Syde® assessed by the Intra-Class Correlation (ICC) for each recording period timepoint. — 12 months reliability assessed by the ICC (Intra-Class Correlation)for each recording period timepoint (baseline, 6 months, 12 months)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.